医学
二尖瓣反流
二尖瓣夹子
功能性二尖瓣反流
心脏病学
倾向得分匹配
内科学
心力衰竭
射血分数
作者
Tomohiro Kaneko,Nobuyuki Kagiyama,Shinya Okazaki,Masashi Amano,Yukio Satô,Yohei Ohno,Masaru Obokata,Kimi Sato,Kojiro Morita,Shunsuke Kubo,Yuki Izumi,Masahiko Asami,Yusuke Enta,Shinichi Shirai,Masaki Izumo,Shingo Mizuno,Yusuke Watanabe,Makoto Amaki,Kazuhisa Kodama,Hisao Otsuki
标识
DOI:10.1093/eurheartj/ehaf511
摘要
Abstract Background and Aims Atrial functional mitral regurgitation (AFMR) commonly affects elderly and frail individuals. The prognostic impact of transcatheter edge-to-edge repair (TEER) for AFMR has not been investigated. Methods Patients with AFMR who underwent TEER were selected from the OCEANMitral registry, and medically managed controls were selected from the REVEALAFMR registry, using an identical AFMR definition. The primary endpoint was a composite of all-cause mortality and heart failure hospitalization. The secondary endpoint was all-cause mortality. Results A total of 1,081 patients (mean age 80.1±8.2 years, 60.5% female) with moderate or severe AFMR were included, of whom 441 underwent TEER and 640 remained on medical treatment. Overlap weighting based on propensity score yielded well-balanced characteristics (n=441 vs. 640; all standardized mean differences <0.01), where TEER was associated with a lower incidence of the primary (hazard ratio [HR] 0.65 [0.43–0.99], p=0.044) and secondary endpoints (HR 0.58 [0.35–0.99], p=0.044). In an exploratory subgroup analysis, favorable outcomes might be pronounced in patients with ≤mild residual AFMR after TEER, while event rates in those with ≥moderate residual AFMR were comparable to the medication group. As sensitivity analyses, inverse probability of treatment weighting (n=158 vs. 173), propensity score matching (n=104 vs. 104), and multivariable Cox regression (n=441 vs. 640) all confirmed favorable associations of TEER with both endpoints. Conclusions In real-world data, TEER for patients with moderate or severe AFMR was associated with a lower incidence of adverse events compared with medical treatment.
科研通智能强力驱动
Strongly Powered by AbleSci AI